Optimal Dosing of Lasmiditan in the Management of Acute Migraine Attack: A Systematic Review and Meta-analysis

BACKGROUND: The current target of migraine treatment is focused on Triptans. Lasmiditan, a non-vasoconstrictive and highly selective 5HT(1F) receptor agonist is a novel therapeutic discovery for migraine for patients with cardiovascular (CV) risk factors or stable cardiovascular diseases and who fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Basutkar, Roopa Satyanarayan, Vinod, Chris Elizabeth, Saju, Shruthi Jaya, Chebrolu, Bhavya, Ponnusankar, Sivasankaran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
AIAN Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232512/
https://www.ncbi.nlm.nih.gov/pubmed/34220057
http://dx.doi.org/10.4103/aian.AIAN_1223_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232512/
https://www.ncbi.nlm.nih.gov/pubmed/34220057
http://dx.doi.org/10.4103/aian.AIAN_1223_20

Ejemplares similares